Argenx (ARGX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argenx Launches Early Safety Study of ARGX-124 With Potential Long-Term Upside for Investors
The study, officially titled “A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-124 in Healthy Adult Participants,” aims to test safety in healthy adults and track how the drug moves through the body. It is an early but important step that could lay the groundwork for future use in immune-related diseases.
The main treatment is ARGX-124, a biological drug candidate given to healthy volunteers to see how well it is tolerated and how the immune system reacts. A placebo is used as a comparison so any changes in safety or lab results can be clearly linked to ARGX-124.
The trial is an interventional Phase 1 study with participants randomly assigned to receive either ARGX-124 or placebo in parallel groups. It is quadruple-blinded, meaning the volunteers, care teams, study doctors, and outcome assessors do not know who is on active drug, which helps reduce bias and keeps the results more reliable.
The study was first submitted on Jan. 22, 2026, marking the formal start of the clinical path for ARGX-124 in humans. The latest update was filed on Mar. 4, 2026, showing that the sponsor is actively managing the protocol and that the program remains in the recruiting phase.
For investors, this update signals that Argenx is adding another pipeline asset on top of its marketed products, which may support a long-term growth story if early safety is clean. While Phase 1 data rarely move the stock sharply by themselves, steady pipeline progress can support sentiment versus peers in the autoimmune and biologics space, and any future positive readouts could become catalysts.
The ARGX-124 Phase 1 trial is now recruiting and remains active, with more detailed information and ongoing updates available on the ClinicalTrials.gov portal.
To learn more about ARGX’s potential, visit the Argenx drug pipeline page.